{"id":8391,"date":"2021-12-16T13:26:59","date_gmt":"2021-12-16T18:26:59","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/lisiraglid-cas-320367-13-3-on-glukagonin-kaltainen-peptidi-1-glp-1-reseptoriagonisti\/"},"modified":"2021-12-16T13:26:59","modified_gmt":"2021-12-16T18:26:59","slug":"lisiraglid-cas-320367-13-3-on-glukagonin-kaltainen-peptidi-1-glp-1-reseptoriagonisti","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/fi\/product\/lisiraglid-cas-320367-13-3-on-glukagonin-kaltainen-peptidi-1-glp-1-reseptoriagonisti\/","title":{"rendered":"Lisiraglid CAS 320367-13-3 on glukagonin kaltainen peptidi-1 (GLP-1) -reseptoriagonisti"},"content":{"rendered":"

Lisiraglid CAS 320367-13-3 on glukagonin kaltainen peptidi-1 (GLP-1) -reseptoriagonisti<\/strong><\/h2>\n

Tuotteen nimi: Liksisenatidi
\nSynonyymit: Liksisenatidi, >98 %; Liksisenatidi
\nMW: 4858.53
\nEINECS:
\nTuoteluokat:
\nMol-tiedosto: 320367-13-3.mol<\/p>\n

Lisiraglidi on glukagonin kaltainen peptidi-1 (GLP-1) reseptoriagonisti, hormoni, joka auttaa normalisoimaan verensokeritasoja. L\u00e4\u00e4kkeen turvallisuutta ja tehoa arvioitiin 10 kliinisess\u00e4 tutkimuksessa, joihin osallistui yhteens\u00e4 5 400 tyypin 2 diabetesta sairastavaa potilasta. N\u00e4iss\u00e4 tutkimuksissa lisiramidia arvioitiin sek\u00e4 monoterapiana ett\u00e4 yhdistelm\u00e4n\u00e4 muiden FDA:n hyv\u00e4ksymien diabetesl\u00e4\u00e4kkeiden kanssa, mukaan lukien metformiini, sulfonyyliureat, pioglitatsoni ja perusinsuliini. N\u00e4iss\u00e4 tutkimuksissa lisiramidin k\u00e4ytt\u00f6 paransi glykoituneen hemoglobiinin (veren glukoosipitoisuuden indikaattori) tasoa. Lis\u00e4ksi yli 6 000 tyypin 2 diabetesta sairastavaa potilasta, joilla oli riski saada ateroskleroottinen syd\u00e4n- ja verisuonitauti, hoidettiin lisiramidilla tai lumel\u00e4\u00e4kett\u00e4 Cardiovascular Outcomes Trial -tutkimuksessa. Lisiramidin k\u00e4ytt\u00f6 n\u00e4ill\u00e4 potilailla ei lis\u00e4nnyt haitallisten kardiovaskulaaristen tapahtumien riski\u00e4. Lisiragidea ei tule k\u00e4ytt\u00e4\u00e4 potilaiden, joilla on tyypin 1 diabetes, tai potilaiden, joilla on lis\u00e4\u00e4ntynyt ketonien tai virtsan veren (diabeettinen ketoasidoosi) hoitoon. Yleisimm\u00e4t lisiramidiin liittyv\u00e4t sivuvaikutukset ovat pahoinvointi, oksentelu, p\u00e4\u00e4ns\u00e4rky, ripuli ja huimaus. Hypoglykemia on toinen yleinen sivuvaikutus potilailla, joita hoidetaan lisiramidilla ja muilla diabetesl\u00e4\u00e4kkeill\u00e4, kuten sulfonyyliureoilla ja\/tai perusviljelm\u00e4ll\u00e4. Lisiragibilla tehdyiss\u00e4 kliinisiss\u00e4 tutkimuksissa on lis\u00e4ksi raportoitu vaikeita yliherkkyysreaktioita (mukaan lukien yliherkkyys).<\/p>\n

Liksisenatidi on t\u00e4ll\u00e4 hetkell\u00e4 diabeteksen hoitoon k\u00e4ytetty l\u00e4\u00e4ke, ja se on my\u00f6s GLP-1-reseptorin agonisti. Liksisenatidi (Lyxumia) on hyv\u00e4ksytty markkinointiin Euroopassa vuonna 2013 ja se on Liksisenatidiin perustuva ruiskeena diabeteksen hoitomuoto, joka annetaan kerran vuorokaudessa yhdess\u00e4 muiden l\u00e4\u00e4kkeiden tai insuliinin kanssa potilaille, joiden verensokeriarvoja saadaan hallintaan vain l\u00e4\u00e4kkeill\u00e4.< &>
\n Huomautus Lisiraglidista CAS 320367-13-3<\/strong>
\nVain tutkimusk\u00e4ytt\u00f6\u00f6n, ei ihmisk\u00e4ytt\u00f6\u00f6n<\/p>\n","protected":false},"excerpt":{"rendered":"

Tuotteen nimi: Lixisenatide
\nAcetate;Lixisenatide USP\/EP\/BP
\nCAS: 320367-13-3
\nMF: C215H347N61O65S
\nMW: 4858.53
\nMol File: 320367-mol3<\/p>\n","protected":false},"featured_media":2100,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[340],"product_tag":[1263],"class_list":{"0":"post-8391","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-diabetes-peptidi","7":"product_tag-lisiraglide-cas-320367-13-3-is-a-glucagon-like-peptide-1-glp-1-receptor-agonist-fi","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product\/8391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/comments?post=8391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/media\/2100"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/media?parent=8391"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_brand?post=8391"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_cat?post=8391"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_tag?post=8391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}